These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30636363)

  • 1. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.
    Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG
    Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
    Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
    Perfect JR; Cornely OA; Heep M; Ostrosky-Zeichner L; Mullane KM; Maher R; Croos-Dabrera R; Lademacher C; Engelhardt M; Chen C; Marty FM
    Mycoses; 2018 Jul; 61(7):420-429. PubMed ID: 29570857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study.
    Ergün M; Jansen AME; Hilbrands LB; de Kort E; Kunst H; Reijers MHE; Schouten JA; Verweij PE; Brüggemann RJM
    J Antimicrob Chemother; 2024 Aug; 79(8):1801-1810. PubMed ID: 38935893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isavuconazole use and TDM in real-world pediatric practice.
    Fernández Ledesma B; Mendoza-Palomar N; Melendo Pérez S; Fernández-Polo A; Renedo Miró B; Pau Parra A; Luque Pardos S; Grau Cerrato S; Vima Bofarull J; Martín-Gómez MT; Pujol Jover M; Benítez-Carbante MI; Díaz de Heredia C; Soler-Palacin P
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0082923. PubMed ID: 37962334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients.
    Monzó-Gallo P; Lopera C; Badía-Tejero AM; Machado M; García-Rodríguez J; Vidal-Cortés P; Merino E; Calderón J; Fortún J; Palacios-Baena ZR; Pemán J; Sanchis JR; Aguilar-Guisado M; Gudiol C; Ramos JC; Sánchez-Romero I; Martin-Davila P; López-Cortés LE; Salavert M; Ruiz-Camps I; Chumbita M; Aiello TF; Peyrony O; Puerta-Alcalde P; Soriano A; Marco F; Garcia-Vidal C
    Int J Infect Dis; 2024 Jul; 144():107070. PubMed ID: 38663477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.
    Rausch CR; DiPippo AJ; Bose P; Kontoyiannis DP
    Clin Infect Dis; 2018 Oct; 67(10):1610-1613. PubMed ID: 29771293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
    Fung M; Schwartz BS; Doernberg SB; Langelier C; Lo M; Graff L; Tan M; Logan AC; Chin-Hong P; Babik JM
    Clin Infect Dis; 2018 Sep; 67(7):1142-1143. PubMed ID: 29617983
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.
    Cornu M; Bruno B; Loridant S; Navarin P; François N; Lanternier F; Amzallag-Bellenger E; Dubos F; Mazingue F; Sendid B
    BMC Pharmacol Toxicol; 2018 Dec; 19(1):81. PubMed ID: 30522521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.
    Fernández-Ruiz M; Bodro M; Gutiérrez Martín I; Rodriguez-Álvarez R; Ruiz-Ruigómez M; Sabé N; López-Viñau T; Valerio M; Illaro A; Fortún J; Salto-Alejandre S; Cordero E; Fariñas MDC; Muñoz P; Vidal E; Carratalà J; Goikoetxea J; Ramos-Martínez A; Moreno A; Aguado JM;
    Transplantation; 2023 Mar; 107(3):762-773. PubMed ID: 36367924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).
    Kovanda LL; Desai AV; Lu Q; Townsend RW; Akhtar S; Bonate P; Hope WW
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4568-76. PubMed ID: 27185799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of isavuconazonium sulfate and its active metabolite isavuconazole in healthy dogs.
    McQuinn E; Mochel JP; Borts D; Hanzlicek AS; Allenspach K; Palerme JS
    PLoS One; 2024; 19(7):e0305766. PubMed ID: 39012876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients.
    Silva JT; Husain S; Aguado JM
    Transpl Int; 2023; 36():11845. PubMed ID: 38161768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of the Rationale for Therapeutic Drug Monitoring of Isavuconazole: A Case Report with a Lung Transplant Recipient.
    Dvořáčková E; Zajacová A; Havlín J; Klapková E; Lischke R; Slanař O; Šíma M
    Prague Med Rep; 2023; 124(4):444-448. PubMed ID: 38069649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic and budgetary impact evaluation of isavuconazole (Cresemba®) versus voriconazole (Vfend®) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system.
    Araujo GLV; Murta Amaral L; Ponzio V; Rocha JL
    PLoS One; 2024; 19(3):e0299056. PubMed ID: 38427635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological management of invasive mold infections in solid organ transplant recipients.
    Fernández-Ruiz M
    Expert Opin Pharmacother; 2024 Feb; 25(3):239-254. PubMed ID: 38436619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the Use and Efficacy of Isavuconazonium Sulfate in a Pediatric Oncology and Stem Cell Transplant Population: A Single Institution Retrospective Review.
    Kunvarjee B; Siver M; Mathew S; Steiger S; Lee YJ; Spitzer B
    J Pediatr Hematol Oncol; 2024 Mar; 46(2):e143-e146. PubMed ID: 38237014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID-19.
    Bertram R; Naumann HT; Bartsch V; Hitzl W; Kinzig M; Haarmeyer GS; Baumgärtel M; Geise A; Muschner D; Nentwich J; John S; Sörgel F; Steinmann J; Höhl R
    Mycoses; 2023 Dec; 66(12):1071-1078. PubMed ID: 37700457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment on "Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies" and "High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints".
    Kong L; Alffenaar JC; Stocker SL
    Clin Pharmacokinet; 2024 May; 63(5):731-733. PubMed ID: 38573478
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube.
    Bury D; Wolfs TFW; Ter Heine R; Muilwijk EW; van der Elst KCM; Tissing WJE; Brüggemann RJM
    J Antimicrob Chemother; 2023 Dec; 78(12):2886-2889. PubMed ID: 37864491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.